Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer.

TitleVal66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer.
Publication TypeJournal Article
Year of Publication2016
AuthorsDooley LN, Ganz PA, Cole SW, Crespi CM, Bower JE
JournalJ Affect Disord
Volume197
Pagination43-50
Date Published2016 Jun
ISSN1573-2517
Abstract

BACKGROUND: Inflammation contributes to the development of depression in a subset of individuals, but risk factors that render certain individuals particularly vulnerable to inflammation-associated depression are undetermined. Drawing from animal studies showing that reduced neuroplasticity mediates effects of inflammation on depression, we hypothesized that individuals genetically predisposed to lower levels of neuroplasticity would be more susceptible to inflammation-associated depression. The current study examined whether the Met allele of the BDNF Val66met polymorphism, which predisposes individuals to reduced levels of brain-derived neurotrophic factor (BDNF), a protein vital for neuroplasticity, moderates the association between inflammation and depressive symptoms.

METHODS: Our sample was 112 women with early-stage breast cancer who had recently completed cancer treatment, which can activate inflammation. Participants provided blood for genotyping and assessment of circulating inflammatory markers, and completed a questionnaire assessing depressive symptoms, including somatic, affective, and cognitive dimensions.

RESULTS: There was a significant interaction between C-reactive protein (CRP) and the BDNF Val66met polymorphism in predicting cognitive depressive symptoms (p=.004), such that higher CRP was related to more cognitive depressive symptoms among Met allele carriers, but not among Val/Val homozygotes. Post-hoc longitudinal analyses suggested that, for Met carriers, higher CRP at baseline predicted higher cognitive depressive symptoms across a one-year follow-up period (p<.001).

CONCLUSION: The BDNF Met allele may be a risk factor for inflammation-associated cognitive depressive symptoms among breast cancer survivors. Women with breast cancer who carry this genotype may benefit from early identification and treatment.

LIMITATION: BDNF genotype is an indirect measure of BDNF protein levels.

DOI10.1016/j.jad.2016.02.059
Alternate JournalJ Affect Disord
PubMed ID26967918
PubMed Central IDPMC4836957
Grant ListP30 AG017265 / AG / NIA NIH HHS / United States
P30 AG028748 / AG / NIA NIH HHS / United States
P30-AG017265 / AG / NIA NIH HHS / United States
P30-AG028748 / AG / NIA NIH HHS / United States
P30CA016042 / CA / NCI NIH HHS / United States
R01 CA 109650 / CA / NCI NIH HHS / United States
R01 CA109650 / CA / NCI NIH HHS / United States
R01 CA160427 / CA / NCI NIH HHS / United States
R24 HD041022 / HD / NICHD NIH HHS / United States
T32 AG033533 / AG / NIA NIH HHS / United States
T32-AG033533 / AG / NIA NIH HHS / United States
T32GM08903 / GM / NIGMS NIH HHS / United States